Skip to main content
. 2021 Mar 18;14:44. doi: 10.1186/s13045-021-01055-9

Fig. 1.

Fig. 1

Therapies in development vs approved therapies for CML in the 3L + setting. 3L third line, allo-SCT allogeneic stem cell transplant, ATP adenosine triphosphate, CML chronic myeloid leukemia, STAMP Specifically Targeting the ABL Myristoyl Pocket, TKI tyrosine kinase